T-cell tolerant fraction as a predictor of immune-related adverse events.
Jared OstmeyerJason Y ParkMitchell S von ItzsteinDavid HsiehchenFarjana FattahMary GwinRodrigo CatalanShaheen KhanPrithvi RajEdward K WakelandYang XieDavid E GerberPublished in: Journal for immunotherapy of cancer (2023)
Among patients receiving ICI, the baseline T-cell tolerant fraction may serve as a predictor of clinically significant irAEs.
Keyphrases